[1]董志章,甘一峰,张易南,等.他氟前列素治疗开角型青光眼的疗效观察[J].眼科新进展,2018,38(9):856-860.[doi:10.13389/j.cnki.rao.2018.0202]
　DONG Zhi-Zhang,GAN Yi-Feng,ZHANG Yi-Nan,et al.The efficacy and safety of Tafluprost as a therapy for patients with primary open angle glaucoma[J].Recent Advances in Ophthalmology,2018,38(9):856-860.[doi:10.13389/j.cnki.rao.2018.0202]
点击复制

他氟前列素治疗开角型青光眼的疗效观察/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年9期
页码:
856-860
栏目:
应用研究
出版日期:
2018-09-05

文章信息/Info

Title:
The efficacy and safety of Tafluprost as a therapy for patients with primary open angle glaucoma
作者:
董志章; 甘一峰; 张易南; 郑海华
325200　浙江省温州市，温州医科大学附属第二医院眼科（董志章，张易南，郑海华）；325200　浙江省温州市，温州医科大学附属第二医院急诊科（甘一峰）
Author(s):
DONG Zhi-Zhang; GAN Yi-Feng; ZHANG Yi-Nan; ZHENG Hai-Hua
Department of Ophthalmology，the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University （DONG Zhi-Zhang，ZHANG Yi-Nan，ZHENG Hai-Hua），Wenzhou 325200，Zhejiang Province，China；Department of Emergency，the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University （GAN Yi-Feng），Wenzhou 325200，Zhejiang Province，China
关键词:
开角青光眼; 他氟前列素; 眼压
Keywords:
open angle glaucoma; tafluprost; intraocular pressure
分类号:
R775
DOI:
10.13389/j.cnki.rao.2018.0202
文献标志码:
A
摘要:
目的　探讨他氟前列素滴眼液对初始用药、单药或多种药物降压控制不佳的开角型青光眼患者的降眼压疗效。方法　将66例116眼诊断为原发性开角型青光眼患者纳入本研究，分为首选治疗组18例36眼、联合用药组26例38眼和替换治疗组22例42眼。每晚使用他氟前列素滴眼液1次，每次一滴。在治疗前以及治疗后4周和12周进行Goldmann压平眼压计测量眼压，测量时间均为早上8-9点；进行视力、裂隙灯下眼前段检查、角膜荧光素染色及眼底镜检查；在用药前与治疗后12周行Humphery视野检查，记录各组结果并进行相关统计学分析。结果　首选治疗组治疗前眼压为（24.6±3.6）mmHg（1 kPa=7.5 mmHg）；治疗后4周和12周眼压分别为（18.8±1.5）mmHg、（18.6±1.7）mmHg，分别下降（5.7±2.1）mmHg、（6.1±2.3）mmHg，与治疗前比较，差异均有统计学意义（t=14.365、17.238；均为P＜0.001）。联合用药组治疗前眼压为（25.7±5.7）mmHg；治疗后4周和12周眼压分别为（18.7±3.4）mmHg和（17.4±3.2）mmHg，分别下降（6.6±3.5）mmHg、（6.8±3.7）mmHg，与治疗前比较，差异均有统计学意义（t=12.840、13.365；均为P＜0.001）。替换治疗组治疗前眼压为（22.8±5.6）mmHg；治疗后4周和12周眼压分别为（17.1±3.2）mmHg、（16.2±2.6）mmHg，分别下降（5.6±3.8） mmHg、（6.6±4.2）mmHg；其中替换β受体阻滞剂与前裂腺素类药物降压治疗，治疗后4周与12周眼压下降幅度在替换β阻滞剂组（5.0±4.1）mmHg、（6.3±4.1） mmHg，在替换PG类药物组为（5.8±2.5）mmHg、（6.4±4.7）mmHg，治疗后12周同治疗前比较，差异均有统计学意义（t=12.095、13.070；均为P＜0.001）。共有7眼患者出现不良反应，为轻到中度结膜充血，未见角膜染色。治疗前视野缺损为（5.4±1.8）dB，治疗后12周为（5.6±1.4）dB，治疗前后差异无统计学意义（P>0.05）。结论　他氟前列素滴眼液能有效降低原发性开角型青光眼患者的眼压；对首选用药、替代治疗及联合用药，他氟前列素滴眼液均能有效控制眼压。
Abstract:
Objective　To evaluate the efficacy of Tafluprost for intraocular pressure (IOP) in patients with primary open angle glaucoma.Methods　This study included 66 adult patients with 116 eyes who were diagnosed as primary open-angle glaucoma（POAG）.These patients were grouped into first choice group with 36 eyes in 18 patients,the combination group with 38 eyes in 26 patients and the alternative treatmetn group with 42 eyes in 22 patients.All the patients were treated with Tafluprost 0.0015% once every night.The IOP measurements by Goldmannapplanation tonometer,the visual acuity,slit lamp microscope examination,corneal fluorescein test and fundus examination were conducted before treatment,4 weeks and 12 weeks after treatment.IOP measurements were performed at 8-9 AM at the follow-up visits.The vision field was tested before treatment and 12 weeks after the medication.All results documented and statistical analyzed.Results　For patients in first choice group of Tafluprost,the mean IOP was (24.6±3.6)mmHg (1 kPa=7.5 mmHg) before treatment,and after treatment for 4 weeks and 12 weeks,the mean IOP was (18.8±1.5)mmHg and (18.6±1.7)mmHg,respectively,and the decrease of IOP was (5.7±2.1)mmHg and (6.1±2.3)mmHg,respectively.By compared with before treatment,the difference was statistically significant (t=14.365,17.238;P<0.001).The IOP was significantly decreased.In the combination group,the average IOP was (25.7±5.7)mmHg before treatment,and after 4 weeks and 12 weeks of treatment,the average IOP was (18.7±3.4)mmHg and (17.4±3.2)mmHg,respectively,and the average decrease of IOP was (6.6±3.5)mmHg,(6.8±3.7)mmHg after treatment,respectively.Compared with before treatment,the difference was statistically significant (t=12.84,13.365;all P<0.001).In the alternative treatment group,the average IOP was (22.8±5.6)mmHg,(17.1±3.2)mmHg and (16.2±2.6)mmHg for before treatment,4 weeks and 12 weeks after treatment,respectively,and the average decrease of IOP was (5.6±3.8)mmHg and (6.6±4.2)mmHg for 4 weeks and 12 weeks of medication,respectively.In the replacement of beta receptor blocking agent,the decrease of IOP was about (5.0±4.1)mmHg，(6.3±4.1)mmHg after 4 weeks and 12 weeks of treatment respectively.While replacement of prostaglandin analogs,the decrease of IOP was about (5.8±2.5)mmHg,(6.4±4.7)mmHg after 4 weeks and 12 weeks of treatment,respectively.Compared with before treatment,the difference was significant (t=12.095,13.07;all P<0.001),the IOP was significantly decreased both 4 weeks and 12 weeks after treatment.In terms of side effects,only seven patients were reported with the mild to moderate hyperemia of conjunctiva and no fluorescein staining was detected in the cornea.The mean defect（MD） in visual field before treatment was（5.4±1.8）dB,and (5.6±1.4)dB after treatment,which showed no statistically significant (P>0.05).Conclusion　Tafluprostcould significantly reduce the IOP,and the potential benefits of Tafluprost as a first choice or a combination or a alternative agent can achieve for adequate IOP control in POAG patients.

参考文献/References:

［1］　CIMBERLE M.European glaucoma society releases new guidelines for glaucoma［J］.Ocul Surg News，2014，32（15）：15-18.
［2］　PETERS D，HEIJL A，BRENNER L，BENGTSSON B.Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up［J］.Acta Ophthalmol，2015，93（8）：745-752.
［3］　REN Z Q.The advances of the expert consensus and the first-line medications of topical intraocular pressure-lowering agents in glaucoma treatment［J］.Ophthalmol CHN，2012，21：11-13.
任泽钦.青光眼局部降眼压药专家共识和一线药物的发展［J］.眼科，2012，21（1）：11-13.
［4］　Chinese Ophthalmological Society Glaucoma group.Expert consensus on diagnosis and treatment of primary glaucoma in China［J］.Chin J Ophthalmol，2014，44（9）：862-863.
中华医学会眼科学分会青光眼学组.我国原发性青光眼诊断和治疗专家共识［J］.中华眼科杂志，2014，44（9）：862-863.
［5］　KEATING G M.Tafluprost ophthalmic solution 0.0015%.A Review in glaucoma and ocular hypertension［J］.Clin Drug Invest，2016，36（6）：499-508.
［6］　RODRIGUEZ-ALLER M，GUINCHARD S，GUILLARME D，PUPIER M，JEANNERAT D，GURNY R.New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability，solubility and ocular tolerance［J］.Eur J Pharm Biopharm，2015，95（2）：203-214.
［7］　TANNA A P，LIN A B.Medical therapy for glaucoma：what to add after a prostaglandin analogs［J］?Curr Opin Ophtahlmol，2015，26（2）：116-120.
［8］　HAMACHER T，AIRAKSINEN J，SAARELA V，LIINAMAA M J，RICHTER U，ROPO A.Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension：results from a pharmacodynamics analysis［J］.Acta Ophthalmol Suppl，2008，242：14-19.
［9］　BEIDOE G，MOUSA S A.Current primary open-angle glaucoma treatments and future directions［J］.Clin Ophthalmol，2012，6（1）：699-707
［10］　HOY S M.Tafluprost/Timolol.A review in open-angle glaucoma or ocular hypertension［J］.Drugs，2015，75（15）：1807-1813.
［11］　GE J，LI X，SUN X，HE X，ZHANG H.Randomized parallel group study of 0.001 5% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension comparison with 0.005% latanoprost ophthalmic solution［J］.Jpn J Ophthalmol，2015，51（2）：95-102.
［12］　TAKAGI Y，OSAKI H，YAMASHITA T，KAI Y.Prospective observational post-marketing study of tafluprost 0.0015%/timolol 0.5% combination ophthalmic solution for glaucoma and ocular hypertension：short-term efficacy and safety［J］.Ophthalmol Ther，2016，5（2）：191-206.
［13］　FARIDI U A，SALEH T A，EWINGS P，VENKATESWARAN M，VODDEN J，CLARIDGE K G.Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension，open-angle and normal tension glaucoma［J］.Clin Exp Ophthalmol，2010，38（7）：678-682.
［14］　LANZL I，HAMACHER T，ROSBACH K，RAMEZ M O，ROTHE R，RUZICKOVA E，et al.Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension［J］.Clin Ophthalmol，2013，7：901-910.
［15］　EVE J.Ocular hypertension treatment study［J］.Arch Ophthalmol，2009，127（2）：213.
［16］　EGOROV E，ROPO A.Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma［J］.Eur J Ophthalmol，2010，19（2）：214-222.
［17］　YAMAMOTO T，KITAZAWA Y，NOMA A，MAEDA S，IDO T，et al.The effects of the beta-adrenergic-blocking agents，timolol and carteolol，on plasma lipids and lipoproteins in Japanese glaucoma patients［J］.J Glaucoma，1996，5（4）：252-257.
［18］　HOLLO G，HOMMER A，ANTON LOPEZ A，ROPO A.Efficacy，safety，and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients［J］.J Ocul Pharmacol TH，2014，30（6）：468-475.
［19］　LORENZ K，PFEIFFER N.Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma［J］.Exp Opin Pharmaco，2014，15（15）：2255-2262.
［20］　PFEIFFER N，TRAVERSO CE，LORENZ K，SAARELA V，LIINAMAA J，UUSITALO H，et al.A 6-month study comparing efficacy，safety，and tolerability of the preservative-free fixed combination of tafluprost 0.001 5% and timolol 0.5% versus each of its individual preservative-free components［J］.Adv Ther，2014，31（12）：1228-1246.

备注/Memo

备注/Memo:
浙江省自然科学基金资助（编号：LY18H120009）
更新日期/Last Update: 2018-08-31